替莫唑胺、伊立替康和贝伐珠单抗联合治疗胶质母细胞瘤患者的器官特异性毒性尸检研究
该研究前瞻性收集2009至2019年76例受试者(胶质瘤68例、脑转移8例)的尸检组织,其中24例复发胶质瘤患者接受替莫唑胺、伊立替康和贝伐珠单抗三药联合(TIB)治疗,中位5.5周期。尸检未发现TIB方案急性毒性所致死亡,伊立替康暴露显著增加临床骨髓抑制频率(p=0.05),常见死亡原因为肿瘤进展和吸入性肺炎。
要点
- 尸检未发现贝伐珠单抗、替莫唑胺或TIB方案导致器官或系统毒性,仅偶见骨髓抑制。
- 伊立替康暴露显著增加临床骨髓抑制频率(p=0.05),延长替莫唑胺使用未显著增加。
- 胶质瘤患者最常见死亡原因为肿瘤进展(63.2%,N=43)和吸入性肺炎(48.5%,N=33)。
核心结论
- 尸检未发现接受贝伐珠单抗、替莫唑胺或TIB方案化疗的胶质瘤患者存在器官或系统毒性,无论疗程长短,仅偶见骨髓抑制和临床可逆性骨髓抑制。
- 伊立替康而非延长替莫唑胺使用显著增加复发胶质瘤患者的临床骨髓抑制。
- 死亡原因最常见为胶质瘤进展浸润脑干和吸入性肺炎。
研究设计与样本
- 前瞻性收集2009至2019年76例受试者(胶质瘤68例,44男24女;脑转移8例,5男3女)的尸检组织,行标准H&E染色,14例肾脏样本行电镜检查。
- 其中24例复发胶质瘤患者接受TIB方案治疗,中位5.5周期(范围1-25)。
- 回顾病历按CTCAE 4.03版分析不良事件,采用游泳图可视化治疗组时间线,二元逻辑回归探索治疗策略与骨髓抑制的关联。
主要发现
- 伊立替康暴露显著增加临床骨髓抑制频率(p=0.05)。
- 胶质瘤患者最常见死亡原因为肿瘤进展(63.2%,N=43),其次为吸入性肺炎(48.5%,N=33)。
- 无死亡原因归因于TIB急性毒性。
- 尸检肾脏标本因自溶不适合研究肾脏超微结构病理变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM). Most patients tolerated these regimens well with known side effects of hypertension, proteinuria, and reversible clinical myelosuppression (CM). However, organ- or system- specific toxicities from chemotherapy agents have never been examined by postmortem study. This is the largest cohort used to address this issue in glioma patients. METHODS: Postmortem tissues (from all major systems and organs) were prospectively collected and examined by standard institution autopsy and neuropathological procedures from 76 subjects, including gliomas (N = 68, 44/M, and 24/F) and brain metastases (N = 8, 5/M, and 3/F) between 2009 and 2019. Standard hematoxylin and eosin (H&E) were performed on all major organs including brain specimens. Electronic microscopic (EM) study was carried out on 14 selected subject's kidney samples per standard EM protocol. Medical records were reviewed with adverse events (AEs) analyzed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. A swimmer plot was utilized to visualize the timelines of patient history by treatment group. The binary logistic regression models were performed to explore any associations between treatment strategies and incident myelosuppression. RESULTS: Twenty-four glioma subjects were treated with TIB [median: 5.5 (range: 1-25) cycles] at tumor recurrence. Exposure to IRI significantly increased the frequency of CM (p = 0.05). No unexpected adverse events clinically, or permanent end-organ damage during postmortem examination was identified in glioma subjects who had received standard or prolonged duration of BEV, TMZ or TIB regimen-based chemotherapies except rare events of bone marrow suppression. The most common causes of death (COD) were tumor progression (63.2%, N = 43) followed by aspiration pneumonia (48.5%, N = 33) in glioma subjects. No COD was attributed to acute toxicity from TIB. The study also demonstrated that postmortem kidney specimen is unsuitable for studying renal ultrastructural pathological changes due to autolysis. CONCLUSION: There is no organ or system toxicity by postmortem examinations among glioma subjects who received BEV, TMZ or TIB regimen-based chemotherapies regardless of durations except for occasional bone marrow suppression and reversible myelosuppression clinically. IRI, but not the extended use of TMZ, significantly increased CM in recurrent glioma patients. COD most commonly resulted from glioma tumor progression with infiltration to brain stem and aspiration pneumonia.
引用
- Lu G, Zhu P, Rao M, et al. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. J Neurooncol. 2022. PMID: 36203027. doi:10.1007/s11060-022-04144-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。